The TL-118 anti-angiogenic fixed drug combination has several outstanding advantages:

► All compounds are approved drugs, consequently extensive clinical data is accessible and their safety profile fully established

► Three of the agents included in the combination are non-cytotoxic drugs, and the only cytotoxic agent (Alkylating agent) is administered at a well tolerated dose, comprising a novel cancer therapy expected to induce fewer side effects

► All drugs are orally bioavailable, allowing the combination to be formulated as an oral dosage form, maximizing patient convenience, taken daily in the convenience of patient's home setting and designed for oral self administration

► The drug-combination's direct anti-angiogenic mechanism of action was demonstrated in experimental animal models, and was found to be effective as anti-tumor therapy